{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"49"}],"units":"Participants"}],"description":"Linear regression was utilized to assess the effect of patient prognostic factors on the toxicity rate.","groups":[{"description":"Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG000","title":"RTD (Cohort 1, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG001","title":"RTD (Cohort 2, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG002","title":"RTD (Cohort 3, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG003","title":"RTD (Cohort 2, Phase 2)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Number in each of the arms was insufficient to conduct regression analyses, therefore regression analyses was conducted overall. Participants who were Thalidomide incompatible.","reportingStatus":"POSTED","timeFrame":"Up to 9 years","title":"Incidence of Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}